From Benchtop to Breweries: Transforming Essential Medicine Supply Chains via Whole-Cell Synthetic Biochemistry
Christina Smolke
CEO and Co-Founder, Antheia, Inc.
Adjunct Professor of Bioengineering, Stanford
Friday, April 17, 2026
3:00 p.m., 66-110
Massachusetts Institute of Technology
Cambridge, MA
Abstract
Generational opportunities in pharma are driven by qualitative transitions in manufacturing. Half of today’s essential medicines cannot be made chemically but must be extracted from biological sources. The underlying agricultural supply chains are increasingly vulnerable to changes in climate, weather, and geopolitics. Current practices also cannot adapt quickly enough to respond to changes in demand, whether caused by pandemic or policy. Starting at Caltech and then Stanford, we pioneered whole-cell synthetic biochemistry to realize first-ever microbial production of benzylisoquinoline and tropane alkaloids (e.g., hydrocodone, scopolamine). At Antheia we have since achieved a combined quadrillion-fold improvement in titer and scale. I will discuss our journey from benchtop science to robust and fully scaled synthetic biomanufacturing processes that disrupt some of the oldest supply chains in pharma. I will also highlight the essential role of chemical engineers in making real seamless delivery of drop-in replacement ingredients to a regulated industry.
Bio
Christina Smolke is CEO and co-founder of Antheia, Inc. and Adjunct Professor of Bioengineering at Stanford University. Prior to Antheia, Christina was a Professor of Bioengineering and Chemical Engineering at Stanford University, the Associate Chair of Education in Bioengineering, and an Investigator at the Chan Zuckerberg Biohub. Christina pioneered a whole-cell engineering approach that enables the design and reconstruction of biosynthetic pathways of unprecedented complexity in brewer’s yeast. At Antheia, she has scaled this biosynthesis technology to rebuild the supply chains for some of the most complex and valuable essential medicines known to humankind. Christina’s impact in advancing the frontiers of biotechnology has been recognized with numerous awards, including Nature’s 10, NIH Director’s Pioneer Award, and Novozymes Award for Excellence in Biochemical Engineering.